Background glaucoma Shape Background glaucoma Shape Background glaucoma Shape
Grants > TRPV1: A Novel Neuroprotective Target in Glaucoma Updated On: Jan. 20, 2025
National Glaucoma Research Grant

TRPV1: A Novel Neuroprotective Target in Glaucoma

David Calkins, PhD

Principal Investigator

David Calkins, PhD

Vanderbilt University Medical Center

Nashville, TN, USA

About the Research Project

Program

National Glaucoma Research

Award Type

Standard

Award Amount

$100,000

Active Dates

April 01, 2008 - March 31, 2010

Grant ID

G2008060

Acknowledgement

Recipient of the Thomas R. Lee Award for National Glaucoma Research.

Goals

This research is aimed at understanding how optic nerve fibers respond to eye pressure and whether blunting this response could prevent vision loss in glaucoma. The study will also help identify new drugs to reduce optic nerve loss in glaucoma by making its fibers insensitive to eye pressure.

Summary

Glaucoma is the leading cause of irreversible blindness worldwide and is estimated to afflict some 80 million people by 2020. Most people think of glaucoma as a disease about pressure in the eye, because high pressure is associated with the disease and lowering pressure often is helpful for slowing vision loss in glaucoma. In fact, glaucoma is irreversible because it damages the fibers of the optic nerve, which is part of the brain and therefore limited in its ability to heal. Our research is important because it is the first attempt to understand how these fibers respond to pressure in the eye and whether blunting this response could prevent vision loss in glaucoma. Our team is comprised of neurobiologists with expertise in how nerve fibers respond to pressure. Thus, our research will help identify new drugs that will reduce the loss of the optic nerve in glaucoma by making its fibers insensitive to pressure in the eye.